APA (7th ed.) Citation

Neuzillet, C., Serova, M., Raballand, A., Astorgues-Xerri, L., Riveiro, M., de Gramont, A., . . . Raymond, E. (2012). 402 Dual Inhibition of the MEK and the PI3K-Akt-mTOR Pathways Using GSK1120212 (or UO126) and Everolimus Overcomes Resistance to MEK Inhibitors Used as Single Agents in Pancreatic Cancer Cells. European Journal of Cancer, 48, 122. https://doi.org/10.1016/S0959-8049(12)72200-1

Chicago Style (17th ed.) Citation

Neuzillet, C., et al. "402 Dual Inhibition of the MEK and the PI3K-Akt-mTOR Pathways Using GSK1120212 (or UO126) and Everolimus Overcomes Resistance to MEK Inhibitors Used as Single Agents in Pancreatic Cancer Cells." European Journal of Cancer 48 (2012): 122. https://doi.org/10.1016/S0959-8049(12)72200-1.

MLA (9th ed.) Citation

Neuzillet, C., et al. "402 Dual Inhibition of the MEK and the PI3K-Akt-mTOR Pathways Using GSK1120212 (or UO126) and Everolimus Overcomes Resistance to MEK Inhibitors Used as Single Agents in Pancreatic Cancer Cells." European Journal of Cancer, vol. 48, 2012, p. 122, https://doi.org/10.1016/S0959-8049(12)72200-1.